Close Menu

NEW YORK – Myriad Genetics said today that it has submitted a supplementary premarket approval application with the US Food and Drug Administration for its BRACAnalysis CDx to identify metastatic castration-resistant prostate cancer patients with germline BRCA1/2 mutations, who may respond well to Merck's olaparib (Lynparza).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.